Oxford Biomedica plc (OXB) Q4 2023 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Oxford Biomedica Plc.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:01.574 And 00:00:01.574 -- 00:00:05.400 obviously, good morning to those on the other side of the ocean. 00:00:05.400 -- 00:00:10.989 Thank you so much for joining today's analyst briefing for our 23 00:00:10.989 -- 00:00:16.438 preliminary results. I'm Frank Mathias, the CEO of Oxford Biomedica. 00:00:16.438 -- 00:00:21.046 And it's a pleasure to see so many familiar faces here in this room. 00:00:21.046 -- 00:00:23.690 So thank you for coming. 00:00:23.690 -- 00:00:28.858 to be here to speak to those on the webcast and those joining via 00:00:28.858 -- 00:00:33.866 the conference call lines today. With me, I have our Chief 00:00:33.866 -- 00:00:37.411 Financial Officer, Stuart Painter, 00:00:37.411 -- 00:00:43.040 our Chief Commercial Officer, Dr. Sébastien Ribault, 00:00:43.040 -- 00:00:46.471 and I'm also proud for the first time 00:00:46.471 -- 00:00:51.980 to have joining me Thierry Cournais, our relatively new appointed 00:00:51.980 -- 00:00:58.849 Chief Operating Officer, who is also in charge of the UK operations. 00:00:59.393 -- 00:01:04.462 As I believe that you have all met Stuart and Sébastien before, I will let 00:01:04.462 -- 00:01:09.911 Thierry introduce himself when he starts his section of the presentation 00:01:09.911 -- 00:01:11.911 shortly. 00:01:12.509 -- 00:01:18.178 So looking at 2023, it's obvious that 2023 was a year of transformation 00:01:18.178 -- 00:01:23.226 for Oxford Biomedica as we began building a global pure place 00:01:23.226 -- 00:01:29.216 cell and gene therapy CDMO. Throughout the year, we have met significant 00:01:29.216 -- 00:01:34.291 milestones and celebrated many successes. which have provided me 00:01:34.291 -- 00:01:39.618 and the board with confidence in our new strategy and its ability 00...